U.S. Markets open in 2 hrs 39 mins
  • S&P Futures

    3,773.75
    +8.25 (+0.22%)
     
  • Dow Futures

    30,949.00
    +71.00 (+0.23%)
     
  • Nasdaq Futures

    12,471.00
    +16.00 (+0.13%)
     
  • Russell 2000 Futures

    2,153.20
    +8.70 (+0.41%)
     
  • Crude Oil

    65.38
    +1.55 (+2.43%)
     
  • Gold

    1,695.30
    -5.40 (-0.32%)
     
  • Silver

    25.44
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1940
    -0.0039 (-0.3224%)
     
  • 10-Yr Bond

    1.5500
    0.0000 (0.00%)
     
  • Vix

    27.81
    +1.14 (+4.27%)
     
  • GBP/USD

    1.3822
    -0.0072 (-0.5169%)
     
  • USD/JPY

    108.3680
    +0.3920 (+0.3630%)
     
  • BTC-USD

    47,368.96
    -1,937.70 (-3.93%)
     
  • CMC Crypto 200

    947.85
    -39.36 (-3.99%)
     
  • FTSE 100

    6,677.55
    +26.67 (+0.40%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Recap: Illumina Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Illumina (NASDAQ:ILMN) moved lower in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 28.24% year over year to $1.22, which beat the estimate of $1.11.

Revenue of $953,000,000 unchanged by 0.00% from the same period last year, which beat the estimate of $903,920,000.

Guidance

Illumina Sees FY21 Adj. EPS $5.10-$5.35 vs $6.11 Estimate, Sales Growth 17-20% Year Over Year

Details Of The Call

Date: Feb 11, 2021

Time: 05:00 PM

View more earnings on ILMN

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.illumina.com%2F&eventid=2946880&sessionid=1&key=9FCFF26C230C354F35F2C9200FA2A08D&regTag=&V2=false&sourcepage=register

Recent Stock Performance

52-week high: $460.52

52-week low: $196.78

Price action over last quarter: Up 54.16%

Company Description

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 17% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.